AbbVie Inc (ABBV)vsPAVmed Inc (PAVM)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
PAVM
PAVmed Inc
$8.30
-6.95%
HEALTHCARE · Cap: $61.09M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 86140748% more annual revenue ($61.16B vs $71,000). PAVM leads profitability with a 565.0% profit margin vs 6.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PAVM
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for PAVM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Keeps 565 of every $100 in revenue as profit
Revenue surging 420.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -32.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : PAVM
The strongest argument for PAVM centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 565.0% and operating margin at -13083.0%. Revenue growth of 420.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : PAVM
The primary concerns for PAVM are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while PAVM is a growth play — different risk/reward profiles.
PAVM carries more volatility with a beta of 0.81 — expect wider price swings.
PAVM is growing revenue faster at 420.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
PAVmed Inc
HEALTHCARE · MEDICAL DEVICES · USA
PAVmed Inc. is a medical device company in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?